A MOSAIC OF EVIDENCE: THE CLINICAL AND ECONOMIC BENEFITS OF CERAMIDE-INFUSED SKIN BARRIERS IN OSTOMY CARE
Author(s)
George Skountrianos, BS, MS;
Hollister Incorporated, Sr Manager, HEOR, Libertyville, IL, USA
Hollister Incorporated, Sr Manager, HEOR, Libertyville, IL, USA
OBJECTIVES: Peristomal skin complications (PSCs) following ostomy surgery are associated with increased healthcare resource utilization, poorer clinical outcomes, and reduced health-related quality of life. This study summarizes clinical, economic, and clinician-reported evidence evaluating a ceramide-infused barrier (CIB) compared with non-ceramide-infused ostomy skin barriers.
METHODS: A targeted narrative review synthesized evidence from multiple study designs. Key sources included the ADVOCATE adaptive randomized controlled trial assessing clinical and economic outcomes of CIB versus non-ceramide-infused barriers. Additional evidence was drawn from published cost-effectiveness analyses (CEAs) and budget impact models (BIMs). Multinational real-world product evaluations provided data on peristomal skin condition, wear time, accessory use, and patient- and clinician-reported satisfaction.
RESULTS: Across evidence sources, CIB demonstrated consistent clinical and economic benefits. In ADVOCATE (n=153), mean ostomy-related healthcare costs over 12 weeks were 14% lower with CIB than with control barriers ($223.73 vs $260.19), corresponding to an estimated annual per-patient savings of approximately $158. Patients using CIB experienced fewer PSCs (40.5% vs 55.4%) and higher PSC resolution rates among those with complications (53.1% vs 29.3%). CEAs projected that CIB use over 1 year would result in approximately 160 fewer PSCs, 350 additional quality-adjusted life-days, and $137,000 in healthcare cost savings per 1,000 patients, with CIB economically dominant versus standard barriers in most scenarios. BIMs estimated that 20% adoption could generate annual payer savings of approximately $6.6 million in the United States. Multinational product evaluations (~2,500 patients) found significant improvements in peristomal skin condition (66% of patients), increased wear time (48%), reduced accessory use (35%), along with high patient and clinician satisfaction.
CONCLUSIONS: Evidence from randomized, economic, and real-world sources indicates that ceramide-infused barriers can lead to improvements in peristomal skin outcomes, high patient- and clinician- satisfaction, and reductions in health system costs. These findings support CIB as a clinically and economically beneficial option for ostomy care.
METHODS: A targeted narrative review synthesized evidence from multiple study designs. Key sources included the ADVOCATE adaptive randomized controlled trial assessing clinical and economic outcomes of CIB versus non-ceramide-infused barriers. Additional evidence was drawn from published cost-effectiveness analyses (CEAs) and budget impact models (BIMs). Multinational real-world product evaluations provided data on peristomal skin condition, wear time, accessory use, and patient- and clinician-reported satisfaction.
RESULTS: Across evidence sources, CIB demonstrated consistent clinical and economic benefits. In ADVOCATE (n=153), mean ostomy-related healthcare costs over 12 weeks were 14% lower with CIB than with control barriers ($223.73 vs $260.19), corresponding to an estimated annual per-patient savings of approximately $158. Patients using CIB experienced fewer PSCs (40.5% vs 55.4%) and higher PSC resolution rates among those with complications (53.1% vs 29.3%). CEAs projected that CIB use over 1 year would result in approximately 160 fewer PSCs, 350 additional quality-adjusted life-days, and $137,000 in healthcare cost savings per 1,000 patients, with CIB economically dominant versus standard barriers in most scenarios. BIMs estimated that 20% adoption could generate annual payer savings of approximately $6.6 million in the United States. Multinational product evaluations (~2,500 patients) found significant improvements in peristomal skin condition (66% of patients), increased wear time (48%), reduced accessory use (35%), along with high patient and clinician satisfaction.
CONCLUSIONS: Evidence from randomized, economic, and real-world sources indicates that ceramide-infused barriers can lead to improvements in peristomal skin outcomes, high patient- and clinician- satisfaction, and reductions in health system costs. These findings support CIB as a clinically and economically beneficial option for ostomy care.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO53
Topic
Clinical Outcomes
Topic Subcategory
Clinician Reported Outcomes
Disease
SDC: Gastrointestinal Disorders